Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Primary objective: To determine the maximum tolerated dose based on the incidence of dose
limiting toxicity and the maximum administered dose of AVE8062 administered every 3 weeks in
patients with advanced solid tumors.
Secondary objectives:
- To assess the overall safety profile of the drug.
- To characterize the pharmacokinetic profile of AVE8062 and its active metabolite RPR
258063.
- To evaluate anti-tumor activity of the drug.